Verrica Pharmaceuticals Inc. (VRCA)
VRCA moved a median of -0.01% 30 minutes after news, and -0.19% by the close. How VRCA actually reacts to news — the realized, point-in-time move the market made, measured across 269 labeled events over the last three years with zero look-ahead.
VRCA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 45% | 267 |
| 30-min | -0.01% | 46% | 268 |
| 60-min | 0.00% | 47% | 269 |
| to close | -0.19% | 47% | 269 |
| Middle 50% of VRCA reactions | -2.98% to +1.25% |
|---|---|
| Median reaction (30-min) | -0.01% |
| Measured reactions | 269 |
Half of all Verrica Pharmaceuticals Inc. news events land between -2.98% and +1.25% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How VRCA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 15 | -1.16% | 40% | -7.56% |
| Rating reiterations | 33 | -1.06% | 30% | -3.18% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how VRCA ranks against every other measured name →
That’s how VRCA usually reacts — get an email when it moves on news →Email me when VRCA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to VRCA's baseline. Nothing else.
Recent VRCA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences | Press release | GlobeNewswire | +0.00% | +6.32% | |
| Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences | Press release | GlobeNewswire | +3.75% | -2.17% | |
| Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | +0.00% | -0.76% | |
| Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027 | Press release | GlobeNewswire | -0.80% | +1.20% | |
| Form 10-Q Verrica Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.41% | -4.33% | |
| Form 8-K Verrica Pharmaceuticals For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +1.41% | -4.33% | |
| Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital | Press release | GlobeNewswire | +1.41% | -4.33% | |
| Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results | Press release | GlobeNewswire | +1.41% | -4.33% | |
| Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026 | Press release | GlobeNewswire | +0.00% | +1.74% | |
| Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel | Press release | GlobeNewswire | — | -2.33% | |
| Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts | Press release | GlobeNewswire | +0.80% | +0.18% | |
| Form 8-K Verrica Pharmaceuticals For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.71% | |
| Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference | Press release | GlobeNewswire | +0.00% | -0.58% | |
| Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ | Press release | GlobeNewswire | +0.51% | +6.66% | |
| Form 10-Q Verrica Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.51% | +6.66% | |
| Form 8-K Verrica Pharmaceuticals For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +0.51% | +6.66% | |
| Form S-8 Verrica Pharmaceuticals | SEC filing · Form S-8 | SEC EDGAR | +0.51% | +6.66% | |
| Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | +0.51% | +6.66% | |
| Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting | Press release | GlobeNewswire | -0.07% | +18.07% | |
| Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026 | Press release | GlobeNewswire | +0.00% | +11.35% | |
| Form ARS Verrica Pharmaceuticals For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.31% | -1.25% | |
| Form DEF 14A Verrica Pharmaceuticals For: Jun 05 | SEC filing · Form DEF | SEC EDGAR | +0.31% | -1.25% | |
| Form DEFA14A Verrica Pharmaceuticals | SEC filing · Form DEFA14A | SEC EDGAR | +0.31% | -1.25% | |
| Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting | Press release | GlobeNewswire | -0.26% | -12.05% | |
| Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference | Press release | GlobeNewswire | +0.00% | +8.73% | |
| Form 10-K Verrica Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +14.26% | +23.96% | |
| Form 8-K Verrica Pharmaceuticals For: Mar 11 | SEC filing · Form 8-K | SEC EDGAR | +14.26% | +23.96% | |
| Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | +14.26% | +23.96% | |
| Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026 | Press release | GlobeNewswire | -0.86% | -0.19% | |
| Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference | Press release | GlobeNewswire | +0.00% | -2.77% | |
| Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer | Press release | GlobeNewswire | -0.89% | -0.71% | |
| Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical | Press release | GlobeNewswire | +2.89% | -0.14% | |
| Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts | Press release | GlobeNewswire | +2.49% | +1.12% | |
| Form 8-K Verrica Pharmaceuticals For: Dec 23 | SEC filing · Form 8-K | SEC EDGAR | +0.61% | +1.47% | |
| Form EFFECT Verrica Pharmaceuticals | SEC filing · Form EFFECT | SEC EDGAR | +2.13% | +2.63% | |
| Form S-3 Verrica Pharmaceuticals | SEC filing · Form S-3 | SEC EDGAR | -2.56% | +15.90% | |
| Form D Verrica Pharmaceuticals | SEC filing · Form D | SEC EDGAR | -1.75% | +0.36% | |
| Form 8-K Verrica Pharmaceuticals For: Nov 23 | SEC filing · Form 8-K | SEC EDGAR | +2.54% | +0.00% | |
| Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway | Press release | GlobeNewswire | +0.23% | +7.03% | |
| Form 10-Q Verrica Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -2.87% | |
| Form 8-K Verrica Pharmaceuticals For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.87% | |
| Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results | Press release | GlobeNewswire | +0.00% | -2.87% | |
| Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting | Press release | GlobeNewswire | +0.11% | +9.01% | |
| Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights | Press release | Business Wire | +1.57% | +1.05% | |
| Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union | Press release | GlobeNewswire | +0.88% | +1.25% | |
| Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting | Press release | GlobeNewswire | -0.45% | -0.90% | |
| Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum | Press release | GlobeNewswire | -0.89% | -2.01% | |
| Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference | Press release | GlobeNewswire | +0.00% | -4.46% | |
| Form 10-Q Verrica Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.84% | -6.53% | |
| Form 8-K Verrica Pharmaceuticals For: Aug 08 | SEC filing · Form 8-K | SEC EDGAR | -2.84% | -6.53% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the VRCA section they belong to.
Where else VRCA is measured.
VRCA earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Achieve Life Sciences, Inc. - Common Shares (ACHV) | 269 | -0.54% | 42% |
| CorMedix Inc. (CRMD) | 269 | -0.42% | 39% |
| CONMED Corporation (CNMD) | 268 | -0.11% | 47% |
| Codexis, Inc. (CDXS) | 267 | 0.00% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Verrica Pharmaceuticals Inc.'s median reaction calculated?
Every labeled VRCA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 269 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 46% of VRCA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does VRCA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.